MB-CART GD2-IL18

N/A

Report date: 2023/09/18 10:44:37

Base Information

Drug NameMB-CART GD2-IL18

Drug Alias NameMB-CART GD2-IL18

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsAnti-GD2

TargetsDisialoganglioside GD2

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMiltenyi Biotec

China Registration ClassN/A

Develop Information

Active CompaniesMiltenyi Biotec

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A